Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.143
Neutral
RSI(14)
43.089
Neutral
STOCH(KDJ)(9,3,3)
66.789
Neutral
ATR(14)
0.547
Low Volatility
CCI(14)
10.819
Neutral
Williams %R
37.574
Buy
TRIX(12,20)
-0.459
Sell
StochRSI(14)
0.000
Sell
Search
Seres Therapeutics Inc
MCRBAdd to Watchlist
7.640USD
-0.390-4.86%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
73.99MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Seres Therapeutics Inc
Currency: USD Updated: 2026-05-15Key Insights
Seres Therapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 143 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 22.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Seres Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Seres Therapeutics Inc Highlights
StrengthsRisks
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Growing
The company is in a growing phase, with the latest annual income totaling USD 789.00K.
Fairly Valued
The company’s latest PE is -0.10, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 2.87M shares, increasing 2.80% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 14.55K shares of this stock.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
22.000
Target Price
+173.97%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Seres Therapeutics Inc is 7.31, ranking 99 out of 382 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high.
Score
Financials
6.91
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.88
Operational Efficiency
10.00
Growth Potential
5.58
Shareholder Returns
7.20
Seres Therapeutics Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Seres Therapeutics Inc is 6.15, ranking 313 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.10, which is -1037971.24% below the recent high of 1035.80 and -4488.18% above the recent low of -4.58.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 143/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Seres Therapeutics Inc is 8.00, ranking 161 out of 382 in the Biotechnology & Medical Research industry. The average price target is 21.00, with a high of 22.00 and a low of 20.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
22.000
Target Price
+173.97%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Seres Therapeutics Inc
MCRB
1
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Seres Therapeutics Inc is 5.67, ranking 308 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 8.98 and the support level at 6.43, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
7.846
Sell
MA10
7.784
Sell
MA20
7.817
Sell
MA50
8.449
Sell
MA100
10.799
Sell
MA200
14.208
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Seres Therapeutics Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 29.64%, representing a quarter-over-quarter increase of 24.25%. The largest institutional shareholder is Invesco, holding a total of 14.55K shares, representing 0.15% of shares outstanding, with 92.07% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Seres Therapeutics Inc is 2.03, ranking 248 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.14. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.11
VaR
+8.21%
240-Day Maximum Drawdown
+75.38%
240-Day Volatility
+111.39%
Return
Best Daily Return
60 days
+10.39%
120 days
+10.39%
5 years
+39.43%
Worst Daily Return
60 days
-9.63%
120 days
-41.66%
5 years
-41.66%
Sharpe Ratio
60 days
-0.21
120 days
-2.40
5 years
-0.07
Risk Assessment
Maximum Drawdown
240 days
+75.38%
3 years
+93.32%
5 years
+97.04%
Return-to-Drawdown Ratio
240 days
+0.12
3 years
-0.33
5 years
-0.19
Skewness
240 days
-0.54
3 years
-0.06
5 years
+0.10
Volatility
Realised Volatility
240 days
+111.39%
5 years
+104.40%
Standardised True Range
240 days
+16.13%
5 years
+61.88%
Downside Risk-Adjusted Return
120 days
-224.79%
240 days
-224.79%
Maximum Daily Upside Volatility
60 days
+49.04%
Maximum Daily Downside Volatility
60 days
+45.70%
Liquidity
Average Turnover Rate
60 days
+0.57%
120 days
+0.98%
5 years
--
Turnover Deviation
20 days
-97.77%
60 days
-97.95%
120 days
-96.48%
Peer Comparison
Biotechnology & Medical Research
Seres Therapeutics Inc
MCRB
5.99 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
